Cargando…
Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
BACKGROUND: Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the cooperation of multiple genomic abnormalities contributes...
Autores principales: | Quijada‐Álamo, Miguel, Pérez‐Carretero, Claudia, Hernández‐Sánchez, María, Rodríguez‐Vicente, Ana‐Eugenia, Herrero, Ana‐Belén, Hernández‐Sánchez, Jesús‐María, Martín‐Izquierdo, Marta, Santos‐Mínguez, Sandra, del Rey, Mónica, González, Teresa, Rubio‐Martínez, Araceli, García de Coca, Alfonso, Dávila‐Valls, Julio, Hernández‐Rivas, José‐Ángel, Parker, Helen, Strefford, Jonathan C., Benito, Rocío, Ordóñez, José‐Luis, Hernández‐Rivas, Jesús‐María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862176/ https://www.ncbi.nlm.nih.gov/pubmed/33634999 http://dx.doi.org/10.1002/ctm2.304 |
Ejemplares similares
-
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
por: Pérez-Carretero, Claudia, et al.
Publicado: (2021) -
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia
por: García-Tuñón, Ignacio, et al.
Publicado: (2017) -
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression
por: Quijada-Álamo, Miguel, et al.
Publicado: (2021) -
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
por: Quijada-Álamo, Miguel, et al.
Publicado: (2020) -
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
por: Forero-Castro, Maribel, et al.
Publicado: (2017)